Market Research Logo

Lennox-Gastaut Syndrome - Pipeline Review, H2 2015

Lennox-Gastaut Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Lennox-Gastaut Syndrome - Pipeline Review, H2 2015’, provides an overview of the Lennox-Gastaut Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lennox-Gastaut Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lennox-Gastaut Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lennox-Gastaut Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lennox-Gastaut Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lennox-Gastaut Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lennox-Gastaut Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Lennox-Gastaut Syndrome Overview
Pipeline Products for Lennox-Gastaut Syndrome - Overview
Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis
Lennox-Gastaut Syndrome - Therapeutics under Development by Companies
Lennox-Gastaut Syndrome - Therapeutics under Investigation by Universities/Institutes
Lennox-Gastaut Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Lennox-Gastaut Syndrome - Products under Development by Companies
Lennox-Gastaut Syndrome - Products under Investigation by Universities/Institutes
Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development
Eisai Co., Ltd.
GW Pharmaceuticals Plc
INSYS Therapeutics, Inc.
Lennox-Gastaut Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epidiolex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRP-2945 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
perampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lennox-Gastaut Syndrome - Recent Pipeline Updates
Lennox-Gastaut Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome
May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome
Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug
Dec 05, 2014: Eisai Presents New Data on Rufinamide at the 68th Annual American Epilepsy Society Meeting
Oct 15, 2014: U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome
Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome
May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome
Feb 28, 2014: GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex in the Treatment of Lennox-Gastaut Syndrome
Jul 26, 2013: Mylan Confirms First-to-File Patent Challenge Relating to BANZEL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lennox-Gastaut Syndrome, H2 2015
Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Lennox-Gastaut Syndrome - Pipeline by Eisai Co., Ltd., H2 2015
Lennox-Gastaut Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2015
Lennox-Gastaut Syndrome - Pipeline by INSYS Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Lennox-Gastaut Syndrome Therapeutics - Recent Pipeline Updates, H2 2015
List of Figures
Number of Products under Development for Lennox-Gastaut Syndrome, H2 2015
Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report